William P. Harris, MD of Seattle Cancer Care Alliance discusses the treatment trends for upper gastrointestinal cancers, which include targeted…
Browsing: Acute Lymphoblastic Leukemia
William P. Harris, MD of Seattle Cancer Care Alliance explains some of the common questions asked regarding the phase II…
William P. Harris, MD of Seattle Cancer Care Alliance discusses metastatic pancreatic cancer for the 2017 ASCO Annual Meeting in…
Julie R. Gralow, MD of Seattle Cancer Care Alliance gives an overview of her presentation, SWOG S0221 updated: Randomized comparison…
Julie R. Gralow, MD of Seattle Cancer Care Alliance explains the impact of the trial on clinical practice, arguing that…
Davendra Sohal, MD of Cleveland Clinic discusses the treatment trends for pancreatic cancer, which include understanding the mechanisms of resistance…
Davendra Sohal, MD of Cleveland Clinic discusses the impact of perioperative chemotherapy on management of resectable pancreatic cancer. This was…
Davendra Sohal, MD of Cleveland Clinic gives an overview of his presentation, Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable…
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center discusses the impact of the talimogene laherparepvec and…
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center talks of his hopes for the expansion of…
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center discusses the most exciting and interesting presentations coming…
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center talks of the common questions most physicians ask…
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center gives an overview of his presentation which focused…
Bernardo H. Goulart, MD, MS of Seattle Cancer Care Alliance explains the impact of natural language processing (NLP) on future…
Bernardo H. Goulart, MD, MS of Seattle Cancer Care Alliance discusses the use of natural language processing (NLP) for patients…
Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center gives an overview of…
Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center discusses a collaborated study…
Michael J. Birrer, MD, PhD discusses his role as newly appointed director for the University of Alabama at Birmingham Comprehensive…
Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center gives an overview of…
Manmeet S. Ahluwalia, MD of Cleveland Clinic discusses three abstracts presented at ASCO 2017, highlighting the management of brain metastases…
Manmeet S. Ahluwalia, MD of Cleveland Clinic gives an overview of his presentation, What Drives Patient Outcomes in Brain Metastases:…
Vivek Subbiah, MD of MD Anderson Cancer Center discusses the impact of his study of vemurafenib in NSCLC patients on…
Vivek Subbiah, MD of MD Anderson Cancer Center discusses the exciting and new data presented at ASCO, which shows promise…
Vivek Subbiah, MD of MD Anderson Cancer Center gives an overview of his presentation, which focused on the use of…
Alan P. Venook, MD of UCSF Helen Diller Family Comprehensive Cancer Center gives an overview of his presentation, which focused…
Alan P. Venook, MD of UCSF Helen Diller Family Comprehensive Cancer Center gives an overview of the exciting presentations discussed…
Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute discusses the common questions and concerns regarding her presentation on commercially prescribed…
Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute gives an overview of her presentation, Tumor response dynamics of advanced non-small-cell…
Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute discusses the treatment trends for lung cancer and oncology overall, which include…
Alok Khorana, MD of Cleveland Clinic gives an overview his presentation, which focuses on time to initiating (TTI) cancer therapy…
Alok Khorana, MD of Cleveland Clinic discusses the skepticism surrounding timing to initiating (TTI) cancer therapy. This was recorded at…
Alok Khorana, MD of Cleveland Clinic gives an overview of the treatment trends for gastrointestinal cancers, which includes the use…
Daniel A. Goldstein, MD of Davidoff Cancer Center gives an overview of the treatment trends for non-small cell lung cancer…
Daniel A. Goldstein, MD of Davidoff Cancer Center discusses the impact of weight-based dosing on patients’ affordability of the drug.…
Daniel A. Goldstein, MD of Davidoff Cancer Center explains the questions regarding the equivalence of dosing in milligrams versus milligrams…
Daniel A. Goldstein, MD of Davidoff Cancer Center gives an overview of his presentation, involving dosing of pembrolizumab in non-small…
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the challenges of the AIM2CERV…
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the take-home message coming out…
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center explains the importance of targeting HPV-associated…
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center explains the goal of the AIM2CERV…
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the use of AIM2CERV’s axalimogene…
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center gives an overview of his presentation,…
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the impact of the AIM2CERV…
Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. discusses the most common questions he has been asked regarding the ENCORE…
Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. gives an overview of a few presentations that he finds the most…
Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. gives an overview of his presentation, Abstract #9529 ENCORE 601: A phase…
Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. discusses the treatment trends in 2017 for advanced melanoma. This was recorded…
Krishnansu S. Tewari, MD of University of California, Irvine explains what CA4P is. CA4P is a vascular disrupting agent (VDA),…
Krishnansu S. Tewari, MD of University of California, Irvine discusses the most recent results from the FOCUS trial, including the…
Krishnansu S. Tewari, MD of University of California, Irvine gives an overview of the FOCUS trial, which is sponsored by…